lansoprazole has been researched along with rabeprazole in 197 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (4.06) | 18.2507 |
| 2000's | 120 (60.91) | 29.6817 |
| 2010's | 54 (27.41) | 24.3611 |
| 2020's | 15 (7.61) | 2.80 |
| Authors | Studies |
|---|---|
| Bariwal, J; Bhosale, AV; Jagtap, JR; Jain, KS; Kale, AP; Shah, AK; Shelke, SM | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Castillo, R; Hernández-Campos, A; Hernández-Luis, F; Pérez-Villanueva, J; Romo-Mancillas, A; Yépez-Mulia, L | 1 |
| Fako, VE; Liu, JY; Pflug, B; Wu, X; Zhang, JT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bi, Y; Kuberan, B; Might, M; Vankayalapati, H | 1 |
| Bala, V; Chhonker, YS | 1 |
| Beghyn, T; Bosc, D; Charton, J; Deprez, B; Deprez-Poulain, R; Guillaume, V; Herledan, A; Hermant, P; Landry, V; Leroux, F; Liang, W; Pottiez, V; Sheng, L; Tang, WJ; Urata, S; Warenghem, S | 1 |
| Chen, WL; Chen, X; Guo, XK; Jiang, ZY; Li, DD; Wang, YZ; Xu, JJ; You, QD | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Igata, H; Okabe, S | 1 |
| Harada, Y; Ikeda, H; Kawai, T; Saitou, T | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| Morii, M; Takeguchi, N; Tomiyama, Y | 1 |
| Hildebrandt, AG; Kleeberg, U; Krusekopf, S; Ruckpaul, K | 1 |
| Besancon, M; Sachs, G; Shin, JM; Simon, A | 1 |
| Andersson, K; Bayati, A; Lee, H; Lorentzon, P | 1 |
| Hirai, S; Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Watanabe, S | 1 |
| Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T | 1 |
| Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Shiga, M; Takao, Y | 1 |
| Hori, K; Hoshino, U; Kohno, M; Okumura, T; Yamada, M; Yoshimura, T | 1 |
| Shimizu, T; Tamura, Y; Taneike, I; Toyoda, S; Yamamoto, T; Yamashiro, Y | 1 |
| Adachi, K; Amano, K; Fukuda, R; Ishihara, S; Katsube, T; Kawamura, A; Kinoshita, Y; Takashima, T; Watanabe, M; Yuki, M | 1 |
| Thomson, AB | 1 |
| Akamatsu, H; Mikawa, K; Nishina, K; Niwa, Y | 1 |
| Bardou, M | 1 |
| Gerson, LB; Triadafilopoulos, G | 1 |
| Belafsky, PC; Koufman, JA; Postma, GN | 1 |
| Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
| Bhattacharjya, AS; Dean, BB; Ofman, JJ; Siddique, RM; Yamashita, BD | 1 |
| Aoyama, N; Hohda, T; Kasuga, M; Kita, T; Nishiguchi, K; Nishitora, Y; Okumura, K; Sakaeda, T; Sakai, T; Sirasaka, D; Tamura, T; Tanigawara, Y | 1 |
| Caro, JJ; Salas, M; Ward, A | 1 |
| Herszényi, L; Tulassay, Z | 1 |
| Fukushima, Y; Hasegawa, J; Ieiri, I; Ishizaki, T; Kishimoto, Y; Kitano, M; Momiyama, K; Morisawa, T; Morita, T; Nakagawa, K; Okochi, H; Otsubo, K | 1 |
| Kromer, W | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Fukao, K; Homma, M; Itagaki, F; Kohda, Y; Yuzawa, K | 2 |
| Barth, J; Hahne, W | 1 |
| Ishii, H; Kitahora, T; Miyazawa, M; Nagahashi, S; Suzuki, H; Suzuki, K; Suzuki, M | 1 |
| Ohkusa, T; Sato, N | 1 |
| Furuta, T; Shirai, N | 1 |
| Adachi, K; Kinoshita, Y | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 2 |
| Inaba, T; Kawai, K; Miyoshi, M; Mizuno, M; Oguma, K; Okada, H; Take, S; Tsuji, T; Yokota, K | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Dodd, S; Durkin, M; Hall, J; Sloan, S | 1 |
| Asano, T; Fukushima, Y; Hirakawa, J; Ishikawa, T; Katsube, T; Mori, H; Ogawa, K; Ohkawa, S; Otsuka, H; Saitoh, T | 1 |
| Abe, H; Arita, T; Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S | 1 |
| Sachs, G; Shin, JM | 1 |
| Frissora, C; Katz, PO | 1 |
| Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H | 1 |
| Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM | 1 |
| Aoyama, N; Baba, T; Kakumoto, M; Kasuga, M; Kawahara, Y; Kirita, S; Kita, T; Kurimoto, Y; Okamura, N; Okumura, K; Sakaeda, T | 1 |
| Chilton, A; Nwokolo, CU; Pounder, RE; Sercombe, J; Usselmann, B; Williams, MP | 1 |
| Kleeberg, U; Krusekopf, S; Roots, I | 1 |
| Blum, AL; Dorta, G; Jornod, P; Pantoflickova, D; Ravic, M | 1 |
| He, LH; Yan, XM; Yin, Y; You, YH; Zhang, JZ | 1 |
| Hellström, PM; Vitols, S | 1 |
| Delattre, M; Felicio, L; Le, GH; Morreale, AP; Okino, L; Plowman, BK; Schaefer, MG | 1 |
| Balashova, NN; Busarova, GA; Maev, IV | 1 |
| Inaba, T; Ishiki, K; Mizuno, M; Nagahara, Y; Oguma, K; Okada, H; Shiratori, Y; Take, S; Yamamoto, K; Yokota, K; Yoshida, T | 1 |
| Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
| Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Junghard, O; Nilsson-Pieschl, C; Nyman, L; Röhss, K; Wilder-Smith, CH | 1 |
| Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I | 1 |
| Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Homma, M; Itagaki, F; Kohda, Y; Naito, S; Nishimura, M; Ohkohchi, N; Ueda, N; Yuzawa, K | 1 |
| Takeda, H | 1 |
| Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T | 1 |
| Hoshino, E; Ishiyama, A; Tsuchida, T | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Alonso, C; Bernal, JL; del Nozal, MJ; Jiménez, JJ; Toribio, L | 1 |
| Hellström, PM | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Katz, PO | 1 |
| Imase, K; Ishida, H; Itoh, T; Kai, A; Sugano, H; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
| Barry, M; Bennett, K; McGowan, B; Tilson, L | 1 |
| Oh, DS; Ohning, GV; Pisegna, JR | 1 |
| Gerson, LB; Shetler, K; Triadafilopoulos, G | 1 |
| Alvarado, M; Hernández, J; Jiménez, S; Porcel, S; Rodríguez, A | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Habuchi, T; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Isaev, VA | 1 |
| Horikawa, Y; Inoue, M; Kuroiwa, T; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| Calvet, X; Gomollón, F | 1 |
| Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Asaka, M; Kato, M; Nakagawa, M; Nakagawa, S; Shimizu, Y | 1 |
| Gao, N; Guo, YZ; Hu, YR; Jia, LJ; Qiao, HL; Tian, X; Zhang, LR | 1 |
| Inoue, M; Kuroiwa, T; Mieno, H; Nakamura, M; Shimatani, T; Tazuma, S; Xu, J | 1 |
| Cubero, AG; González Sánchez, LA; Mosquera, MR; Pérez Pimiento, AJ; Prieto Lastra, L; Rodríguez Cabreros, MI | 1 |
| Inoue, S; Itoh, H; Katagiri, F; Sato, Y; Takeyama, M | 1 |
| Avorn, J; Canning, C; Dormuth, CR; Glynn, RJ; Maclure, M; Schneeweiss, S | 1 |
| Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP | 1 |
| Miura, M | 1 |
| Clark, DW; Strandell, J | 1 |
| Hunt, RH; Padol, IT; Padol, S; Thabane, M; Yuan, Y | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 1 |
| Adachi, K; Azumi, T; Furuta, K; Kinoshita, Y; Koshino, K; Miki, M | 1 |
| Chiu, YL; Pan, WJ; Pilmer, BL; Täubel, J; Tolman, KG; Warrington, S | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Coté, GA; Ferreira, MR; Howden, CW; Rozenberg-Ben-Dror, K | 1 |
| Andersson, S; Nelander, H; Ohlén, K | 1 |
| Forrester, MB | 1 |
| Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Sagae, Y; Satoh, S; Suzuki, T; Tada, H | 1 |
| Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H | 1 |
| Abudayyeh, S; Agha, A; Graham, DY; Han, C; Lu, M; Malladi, V; Siepman, N | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Aoki, T; Itoi, T; Kawai, T; Kawakami, K; Matsumoto, Y; Mikinori, K; Moriyasu, F; Noguchi, N; Rimbara, E; Sasatsu, M; Takagi, Y; Takei, K; Watanebe, K | 1 |
| Serebrova, SIu | 1 |
| Boyer, K; Tolia, V | 1 |
| Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Furuta, T; Ishizaki, T; Shirai, N; Sugimoto, M | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 1 |
| Habuchi, T; Inoue, K; Kagaya, H; Miura, M; Saito, M; Satoh, S; Suzuki, T | 1 |
| Alonso, C; Bernal, YL; del Nozal, MJ; Jiménez, JJ; Toribio, L | 1 |
| Abe, Y; Goto, J; Hishinuma, T; Horii, T; Iijima, K; Imatani, A; Kikuchi, R; Kobayashi, S; Koike, T; Ohara, S; Shimosegawa, T; Suzuki, K; Yamagishi, H | 1 |
| Andersson, T; Weidolf, L | 1 |
| Hosohata, K; Inui, K; Katsura, T; Masuda, S; Ogura, Y; Oike, F; Takada, Y; Uemoto, S | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Goto, J; Hishinuma, T; Koike, T; Mano, N; Ohara, S; Shimosegawa, T; Suzuki, K; Yamagishi, H; Yamaguchi, H | 1 |
| Furukawa, N; Hata, M; Hayasaka, M; Kimura, H; Minami, K; Niino, T; Osaka, S; Sezai, A; Taoka, M; Unosawa, S; Yoda, M | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Huang, Z; Shi, R; Wang, J; Wang, X; Xu, Z; Yang, Y; Zhang, G; Zhao, F | 1 |
| Pellicano, R | 1 |
| Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K | 1 |
| Hashimoto, H; Hirota, K; Imai, A; Kudo, M; Kushikata, T | 1 |
| Friesen, MH | 1 |
| DAS, R; Edwards, SJ; Lind, T; Lundell, L | 1 |
| Gärtner, P; Knoth, H; Zschimmer, K | 1 |
| Kume, K; Nagato, M; Otsuki, M; Yamasaki, M; Yoshikawa, I | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Cristofari, F; De Francesco, V; Hassan, C; Iegri, C; Zullo, A | 1 |
| Keyhanfar, F; Mahmoudian, M; Motevalian, M; Noubarani, M | 1 |
| Habuchi, T; Hayakari, M; Kagaya, H; Miura, M; Niioka, T; Saito, M; Satoh, S | 1 |
| Niioka, T | 1 |
| Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Namiki, N; Nishino, M; Sugimoto, M; Uchida, S; Watanabe, H; Yamade, M | 1 |
| Howden, CW; Hughes, N; Kahrilas, PJ | 1 |
| Goto, Y; Hamajima, N; Inoue, S; Kamiya, Y; Kawai, S; Kondo, T; Kurata, M; Tamura, T | 1 |
| Hofmann, U; Nies, AT; Resch, C; Rius, M; Schaeffeler, E; Schwab, M | 1 |
| Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Arai, M; Hata, S; Imazeki, F; Katsuno, T; Maruoka, D; Matsumura, T; Nakagawa, T; Suzuki, T; Tanaka, T; Yokosuka, O | 1 |
| Kawahara, K; Moroga, T; Okamura, Y; Takahashi, Y; Takeno, S; Yamashita, S | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Harmon, JW; Hayashi, H; Kitagawa, H; Makino, I; Marti, GP; Matsui, D; Miyashita, T; Murakami, M; Nakagawara, H; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Shah, FA; Tajima, H; Takamura, H | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Bhushan, R; Dixit, S; Dubey, R | 1 |
| Chen, A; Chen, JJ; Hsu, PI; Hsu, WH; Kuo, CH; Kuo, FC; Liu, CJ; Liu, MK; Lu, CY; Su, YC; Wu, DC; Wu, IC; Yu, FJ | 1 |
| Metz, DC; Shah, P; Singh, MH; Yang, YX | 1 |
| Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Chiba, K; Izumo, N; Kato, M; Nishibayashi, T; Shimizu, K; Sugiyama, Y; Terada, K | 1 |
| Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S | 1 |
| Furuta, T; Ichikawa, H; Kagami, T; Kodaira, C; Nishino, M; Sahara, S; Shirai, N; Sugimoto, K; Sugimoto, M; Uotani, T | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Accassat, S; Basset, T; Bertoletti, L; Delavenne, X; Hodin, S; Mismetti, P; Ollier, E | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Gotoda, T; Iwatsuka, K; Kusano, C; Moriyama, M; Suzuki, S | 1 |
| Kato, S; Konuma, T; Kurokawa, Y; Takahashi, S; Tojo, A; Yasu, T | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö | 1 |
| Aydin, F; Caliskan, Y; Ciftci, HS; Demir, E; Karadeniz, MS; Nane, I; Oguz, FS; Tefik, T; Turkmen, A; Yazıcı, H | 1 |
| Fujisawa, T; Horiuchi, A; Imai, R; Kimura, T; Kiyosawa, K; Kubota, D; Maruyama, M; Matsuda, Y; Miyajima, M; Mori, H; Tanaka, N; Tokutake, K; Wada, S | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Robotis, J; Rokkas, T; Tsiodras, S | 1 |
| Hatakeyama, S; Hosogoe, S; Imanishi, K; Ohyama, C; Okamoto, T; Saitoh, F; Suzuki, T; Takashima, T; Tanaka, Y | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Dubský, P; Gyéresi, Á; Hancu, G; Kelemen, H; Noszál, B; Papp, LA; Szabó, ZI; Tóth, G | 1 |
| Kan, LD; Li, LC; Wu, CY; Ying, J; Yu, ZW | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Asahina, A; Kikuchi, S; Nobeyama, Y; Saeki, H | 1 |
| Abu-Rish, EY; Dahabiyeh, LA; Taha, MO | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Huang, X; Liu, Y; Shen, Y; Su, YW; Sun, LN; Wang, YQ; Yang, YQ; Ying, YW; Zhang, XH; Zhang, Y | 1 |
| Chen, G; Li, XM; Mei, D; Ning, LJ; Qin, Y; Zhao, B | 1 |
| Arnaud, B; Arnoult, C; Escoffier, J; Hograindleur, JP; Kaba, M; Le Blévec, E; Martinez, G; Nef, S; Ray, PF; Stévant, I | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Kiryu, Y; Kodaira, N; Matsuzaki, A; Momo, K; Niiyama, K; Sasaki, T; Tanaka, K; Uchikura, T; Watanabe, A | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A | 1 |
| Goto, A; Izumi-Nakaseko, H; Kambayashi, R; Sugiyama, A; Takei, Y | 1 |
44 review(s) available for lansoprazole and rabeprazole
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; Peptic Ulcer; Proton Pump Inhibitors | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in anti-Trichomonas research: An update review.
Topics: Antiparasitic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trichomonas; Trichomonas Infections | 2018 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
[Two cases of ocular damage associated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Vision Disorders | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2000 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Duodenal Ulcer; Enzyme Inhibitors; Esophagitis, Peptic; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Stomach Ulcer; Sulfoxides | 2001 |
Proton pump inhibitors and their drug interactions: an evidence-based approach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Gastrointestinal Agents; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Randomized Controlled Trials as Topic; Ranitidine; Sulfoxides; Treatment Outcome | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Duodenal Ulcer; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Stomach Ulcer; Sulfoxides | 2001 |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Cause and prevention of nocturnal gastric acid breakthrough].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Esophagitis, Peptic; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Ranitidine | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Esomeprazole; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
[Primary care for GEDR].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Circadian Rhythm; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Laparoscopy; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Japan; Lansoprazole; Markov Chains; Meta-Analysis as Topic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic | 2004 |
[PPI: new strategies for GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cytochrome P-450 CYP2C19; Depression, Chemical; Drug Resistance; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexlansoprazole; Genotype; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2006 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cytochrome P-450 CYP2C19; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Controlled Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Lansoprazole; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Duodenal Ulcer; Dyspepsia; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Stomach Ulcer | 2000 |
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Omeprazole; Pain Measurement; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esophagus; Disease Progression; Esophageal Neoplasms; Gastroesophageal Reflux; Humans; Immunologic Factors; Lansoprazole; Neutrophils; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2013 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
47 trial(s) available for lansoprazole and rabeprazole
| Article | Year |
|---|---|
Efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 1995 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 1999 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2000 |
A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Elective Surgical Procedures; Female; Gastric Juice; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pneumonia, Aspiration; Prospective Studies; Rabeprazole; Ranitidine | 2000 |
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2000 |
CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gastrins; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Neutrophils; Omeprazole; Peroxidase; Proton Pump Inhibitors; Pyloric Antrum; Rabeprazole; Stomach Ulcer | 2002 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; DNA; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome | 2003 |
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Cross-Over Studies; Female; Gastric Acid; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Rabeprazole; Urea | 2003 |
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Antacids; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2003 |
Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Digoxin; Drug Interactions; Formularies, Hospital as Topic; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Multivariate Analysis; Omeprazole; Polymorphism, Genetic; Probability; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Statistics, Nonparametric; Treatment Outcome | 2003 |
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Rabeprazole | 2003 |
Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Omeprazole; Rabeprazole; Tacrolimus | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Barrett Esophagus; Benzimidazoles; Esophageal pH Monitoring; Esophagus; Female; Gastric Acid; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Proton-Translocating ATPases; Quality of Life; Rabeprazole; Treatment Outcome | 2005 |
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Dexlansoprazole; Humans; Immunosuppressive Agents; Kidney Transplantation; Kinetics; Lansoprazole; Mixed Function Oxygenases; Models, Molecular; Molecular Structure; Omeprazole; Rabeprazole; Stereoisomerism; Substrate Specificity; Tacrolimus | 2005 |
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Gastric Acid; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Monitoring, Physiologic; Omeprazole; Rabeprazole | 2005 |
Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; China; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Rabeprazole | 2006 |
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Gastric Acidity Determination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Rabeprazole | 2006 |
Comparison of the effects of proton pump inhibitors on human plasma adrenocorticotropic hormone and cortisol levels under the starved condition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adrenocorticotropic Hormone; Adult; Anti-Ulcer Agents; Feeding Behavior; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Lansoprazole; Male; Pituitary-Adrenal System; Proton Pump Inhibitors; Rabeprazole; Starvation | 2006 |
A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Gastric Acidity Determination; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Time Factors | 2006 |
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Cross-Over Studies; Enzyme Inhibitors; Female; Gastric Acidity Determination; Humans; Lansoprazole; Male; Rabeprazole | 2006 |
Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Genes, MDR; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Polymorphism, Genetic; Rabeprazole; Tacrolimus | 2007 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton-Translocating ATPases; Rabeprazole; Surveys and Questionnaires; Treatment Outcome | 2007 |
Failures in a proton pump inhibitor therapeutic substitution program: lessons learned.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aluminum Hydroxide; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Lansoprazole; Magnesium Hydroxide; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Silicic Acid; Treatment Failure | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retreatment; Stomach Diseases; Treatment Outcome | 2007 |
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophagitis; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
Efficacy of a single 24-hour pre-anesthetic dose of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Drug Administration Schedule; Female; Gastric Acidity Determination; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Piperidines; Pneumonia, Aspiration; Preanesthetic Medication; Proton Pump Inhibitors; Rabeprazole; Respiratory Aspiration; Risk Factors; Treatment Outcome; Urologic Surgical Procedures | 2009 |
Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Young Adult | 2010 |
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Gastroscopy; Humans; Lansoprazole; Male; Mucous Membrane; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2012 |
Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Telemetry | 2013 |
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2013 |
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Topics: Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Lansoprazole; Male; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2013 |
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
Topics: Adult; Asian People; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2014 |
In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line, Tumor; Cyclosporine; Dabigatran; Drug Interactions; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Thrombin; Young Adult | 2015 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2016 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Single-Blind Method; Sulfonamides; Treatment Outcome | 2017 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
106 other study(ies) available for lansoprazole and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Antiprotozoal activity of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiprotozoal Agents; Drug Design; Entamoeba histolytica; Giardia lamblia; Humans; Lansoprazole; Omeprazole; Pantoprazole; Parasitic Diseases; Proton Pump Inhibitors; Rabeprazole; Trichomonas vaginalis | 2011 |
Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Repositioning; Fatty Acid Synthases; Humans; Hydrogen-Ion Concentration; Lansoprazole; Palmitic Acid; Palmitoyl-CoA Hydrolase; Protein Structure, Tertiary; Proton Pump Inhibitors | 2015 |
Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Genetic Diseases, Inborn; Humans; Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase; Molecular Structure; Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Small Molecule Libraries; Structure-Activity Relationship | 2017 |
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
Topics: Azoles; Biocatalysis; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Insulysin; Isoindoles; Molecular Structure; Organoselenium Compounds; Structure-Activity Relationship | 2019 |
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone-Lysine N-Methyltransferase; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Molecular Structure; Myeloid-Lymphoid Leukemia Protein; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship | 2020 |
[Discovery and development of the proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benzimidazoles; Depression, Chemical; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Lansoprazole; Microsomes; Omeprazole; Rabeprazole | 1992 |
[Changes in the rat stomach after long-term administration of proton pump inhibitors (AG-1749 and E-3810)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Gastric Acid; Gastrins; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric; Rabeprazole; Rats; Rats, Inbred Strains; Stomach; Vacuoles | 1992 |
Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Cation Transport Proteins; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Lansoprazole; Male; Microsomes; Omeprazole; Potassium; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Wistar; Time Factors | 1994 |
Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; beta-Naphthoflavone; Cell Line; Cytochrome P-450 CYP1A1; Enzyme Activation; Humans; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; RNA, Messenger; Sulfoxides | 1997 |
Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amino Acid Sequence; Animals; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastric Acid; H(+)-K(+)-Exchanging ATPase; Indicators and Reagents; Lansoprazole; Molecular Sequence Data; Omeprazole; Oxidoreductases; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sequence Homology, Amino Acid; Sphingosine; Stomach; Sulfhydryl Compounds; Sulfoxides; Swine | 1997 |
Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Binding Sites; Enzyme Inhibitors; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Humans; Kinetics; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Sulfoxides; Valinomycin | 1997 |
[In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Child, Preschool; Enzyme Inhibitors; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pumps; Rabeprazole; Sulfides | 2000 |
Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Humans; Hydrogen Peroxide; Lansoprazole; Neutrophils; Omeprazole; Phagocytosis; Pirenzepine; Rabeprazole; Superoxides | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studies; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngeal Diseases; Laryngoscopy; Male; Middle Aged; Omeprazole; Pharyngeal Diseases; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Treatment Outcome | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2001 |
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Exons; Female; Humans; Immunosuppressive Agents; Lansoprazole; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Child; Child, Preschool; Drug Costs; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2002 |
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Circadian Rhythm; Cross-Over Studies; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Acidity Determination; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2002 |
Restoration of acid secretion following treatment with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Dithiothreitol; Enzyme Activation; Enzyme Inhibitors; Gastric Acid; Glutathione; H(+)-K(+)-Exchanging ATPase; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Sprague-Dawley; Stomach | 2002 |
Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Interactions; Famotidine; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tacrolimus | 2002 |
Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Antibodies; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2003 |
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Gene Expression Regulation; Humans; Hypericum; Lansoprazole; Omeprazole; Pantoprazole; Plant Preparations; Rabeprazole; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfoxides | 2003 |
[In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Proton Pump Inhibitors; Rabeprazole | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Models, Economic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; Esophagoscopy; Esophagus; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Manometry; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2004 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Chiral separation of omeprazole and several related benzimidazoles using supercritical fluid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohols; Amylose; Benzimidazoles; Chromatography; Lansoprazole; Models, Chemical; Omeprazole; Pantoprazole; Pressure; Rabeprazole; Stereoisomerism; Sulfoxides; Temperature; Time Factors | 2004 |
[Choice of proton pump inhibitors--does it play any role?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drugs, Generic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Tokyo | 2005 |
Cost effective prescribing of proton pump inhibitors (PPI's) in the GMS Scheme.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Community Pharmacy Services; Cost-Benefit Analysis; Drug Costs; Enzyme Inhibitors; Health Care Surveys; Humans; Ireland; Lansoprazole; National Health Programs; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Treatment Failure | 2005 |
Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross Reactions; Drug Hypersensitivity; Enzyme Inhibitors; Female; Humans; Immunoglobulin E; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Skin Tests | 2005 |
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Rabeprazole; Remission Induction; Time Factors | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Cross Reactions; Drug Hypersensitivity; Enzyme Inhibitors; Female; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Skin Tests | 2006 |
A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimidazoles; British Columbia; Cost Savings; Databases, Factual; Drug Utilization Review; Female; Health Services for the Aged; Hospitalization; Humans; Insurance, Pharmaceutical Services; Lansoprazole; Male; Omeprazole; Pantoprazole; Practice Patterns, Physicians'; Rabeprazole; Sulfoxides | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Time Factors | 2006 |
Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost Savings; Esophagitis, Peptic; Female; Formularies, Hospital as Topic; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2007 |
Preparative chiral chromatography and chiroptical characterization of enantiomers of omeprazole and related benzimidazoles.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography; Chromatography, Supercritical Fluid; Circular Dichroism; Enzyme Inhibitors; Lansoprazole; Models, Chemical; Molecular Conformation; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2007 |
Pattern of proton pump inhibitor calls to Texas poison centers, 1998-2004.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Animals; Child; Child, Preschool; Enzyme Inhibitors; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Poison Control Centers; Poisoning; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Texas | 2007 |
[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Acidity Determination; Gastritis; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Muscarinic Antagonists; Omeprazole; Parietal Cells, Gastric; Pirenzepine; Proton Pump Inhibitors; Rabeprazole; Ranitidine; Receptors, Histamine H2; Receptors, Muscarinic | 2007 |
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Humans; Lansoprazole; Liver Function Tests; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Vitamin B 12 | 2008 |
Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mycophenolic Acid; Polymorphism, Single Nucleotide; Prednisolone; Rabeprazole; Retrospective Studies; Tacrolimus | 2008 |
Semipreparative chiral supercritical fluid chromatography in the fractionation of lansoprazole and two related antiulcer drugs enantiomers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chemical Fractionation; Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Chromatography; Chromatography, Supercritical Fluid; Equipment Design; Lansoprazole; Models, Chemical; Pantoprazole; Pharmaceutical Preparations; Rabeprazole; Stereoisomerism; Time Factors | 2008 |
Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Gastric Acid; Gastric Mucosa; Genotype; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Models, Biological; Rabeprazole | 2008 |
Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adjuvants, Immunologic; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Lansoprazole; Liver Transplantation; Living Donors; Male; Middle Aged; Mixed Function Oxygenases; Rabeprazole; Tacrolimus | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Simple quantification of lansoprazole and rabeprazole concentrations in human serum by liquid chromatography/tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, Liquid; Humans; Lansoprazole; Male; Rabeprazole; Sensitivity and Specificity; Tandem Mass Spectrometry | 2008 |
Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anticoagulants; Cardiac Surgical Procedures; Cardiac Tamponade; Female; Hemothorax; Humans; International Normalized Ratio; Lansoprazole; Male; Middle Aged; Postoperative Hemorrhage; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk Factors; Warfarin | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoxazoles; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Zonisamide | 2009 |
Interaction between clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Case-Control Studies; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Myocardial Infarction; Odds Ratio; Omeprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine | 2009 |
Differential pulse polarographic investigation of lansoprazole and rabeprazole using dropping mercury electrode.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acids; Anti-Ulcer Agents; Electrochemistry; Electrodes; Hydrogen-Ion Concentration; Lansoprazole; Mercury; Polarography; Rabeprazole | 2009 |
Long-term treatment with proton pump inhibitor is associated with undesired weight gain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Pressure; Body Mass Index; Body Weight; Case-Control Studies; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Weight Gain | 2009 |
How to manage Helicobacter pylori after sequential therapy failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Ofloxacin; Rabeprazole; Treatment Failure; Treatment Outcome | 2010 |
Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Rabeprazole; Tacrolimus; Time Factors | 2011 |
Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Specimen Collection; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Monitoring; Fluvoxamine; Genotype; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2011 |
Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aminopyrine; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Breath Tests; Carbon Isotopes; Cytochrome P-450 CYP2C19; Female; Genotype; Half-Life; Humans; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2012 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Pharmacogenetics; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2011 |
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biological Transport; Cell Line; Humans; Imidazoles; Immunoblotting; Inhibitory Concentration 50; Lansoprazole; Metformin; Omeprazole; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Protein Binding; Proton Pump Inhibitors; Rabeprazole | 2011 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cytochrome P-450 CYP2C19; Drug Resistance; Endoscopy, Gastrointestinal; Esophageal Neoplasms; Esophagectomy; Genotype; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer Hemorrhage; Pharmacogenetics; Phenotype; Plastic Surgery Procedures; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer; Treatment Outcome; Wound Healing | 2013 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism | 2014 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Secretin; Sensitivity and Specificity; Stomach; Young Adult; Zollinger-Ellison Syndrome | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans.
Topics: Area Under Curve; Cytochrome P-450 CYP2C19; Genotype; Humans; Lansoprazole; Monte Carlo Method; Polymorphism, Genetic; Rabeprazole | 2014 |
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Topics: Calcineurin Inhibitors; Connective Tissue Diseases; Cyclosporine; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Gastrointestinal Diseases; Genotype; Humans; Lansoprazole; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Tacrolimus | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Tokyo | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Body Weight; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Drug Interactions; Drug Monitoring; Female; Hematologic Neoplasms; Humans; Injections, Intravenous; Lansoprazole; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Postoperative Complications; Rabeprazole; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Voriconazole; Young Adult | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
Topics: Adult; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Mycophenolic Acid; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Tacrolimus | 2017 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; Humans; Kidney Failure, Chronic; Lansoprazole; Logistic Models; Magnesium; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Retrospective Studies; Vascular Calcification | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
Chiral separation of lansoprazole and rabeprazole by capillary electrophoresis using dual cyclodextrin systems.
Topics: Cyclodextrins; Electrophoresis, Capillary; Lansoprazole; Limit of Detection; Linear Models; Rabeprazole; Reproducibility of Results; Stereoisomerism | 2019 |
The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; China; Comorbidity; Esomeprazole; Female; Health Care Surveys; Hospitals; Humans; Inappropriate Prescribing; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sex Factors; Stevens-Johnson Syndrome; Sulfonamides | 2020 |
Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments.
Topics: Humans; Lansoprazole; Molecular Docking Simulation; Molecular Structure; Monoacylglycerol Lipases; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Rabeprazole; Substrate Specificity | 2020 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Simultaneous enantioselective determination of omeprazole, rabeprazole, lansoprazole, and pantoprazole enantiomers in human plasma by chiral liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Rabeprazole; Stereoisomerism; Tandem Mass Spectrometry | 2020 |
Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Topics: Acute Kidney Injury; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Lansoprazole; Male; Middle Aged; Product Surveillance, Postmarketing; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Fertilization; Humans; Lansoprazole; Male; Membrane Potentials; Middle Aged; Omeprazole; Pantoprazole; Phosphorylation; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Semen Analysis; Sperm Capacitation; Sperm Maturation; Sperm Motility; Spermatozoa; Young Adult | 2020 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database.
Topics: Cardiovascular Diseases; Cytochrome P-450 CYP2C19; Humans; Lansoprazole; Male; Potassium; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2022 |
The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoplasmic Reticulum Stress; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult | 2023 |
In vivo analysis of acute eletropharmacological effects of proton pump inhibitors using halothane-anesthetized dogs: a translational study of cardiovascular adverse events.
Topics: Animals; Dogs; Halothane; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole | 2023 |